Salud financiera de hoja de balance de Abliva

Salud financiera controles de criterios 4/6

Abliva tiene un patrimonio de los accionistas total de SEK52.9M y una deuda total de SEK0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son SEK63.2M y SEK10.3M respectivamente.

Información clave

Ratio deuda-patrimonio

SEK 0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	SEK 45.25m
Patrimonio	SEK 67.42m
Total pasivo	SEK 8.28m
Activos totales	SEK 75.70m

Actualizaciones recientes sobre salud financiera

Recent updates

Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business

Dec 18

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

Aug 24

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Aug 21

We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate

Oct 13

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Mar 22

How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?

Dec 06

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK38.0M) de ABLI superan a sus pasivos a corto plazo (SEK10.0M).

Pasivo a largo plazo: Los activos a corto plazo de ABLI (SEK38.0M) superan a sus pasivos a largo plazo (SEK321.0K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: ABLI está libre de deudas.

Reducción de la deuda: ABLI no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: ABLI tiene menos de un año de cash runway basado en su flujo de caja libre actual.

Pronóstico de cash runway: ABLI tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 2.9% cada año

Salud financiera de hoja de balance de Abliva

Salud financiera controles de criterios 4/6

Información clave

Actualizaciones recientes sobre salud financiera

Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Recent updates

New major risk - Shareholder dilution

New major risk - Financial position

Abliva AB (publ) Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

Abliva AB (Publ) Announces Completion of 24 Weeks of Dosing in Wave 1 of the Falcon Study of KL1333 in Primary Mitochondrial Disease

New minor risk - Shareholder dilution

Abliva AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 46.093054 million.

Full year 2023 earnings released: kr0.09 loss per share (vs kr0.12 loss in FY 2022)

New minor risk - Share price stability

Abliva (STO:ABLI) Is In A Strong Position To Grow Its Business

Abliva AB (publ) to Report Nine Months, 2024 Results on Nov 21, 2024

Abliva AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Abliva AB (publ) Achieves Important Milestone in the Ongoing FALCON Study

Abliva AB (publ), Annual General Meeting, May 23, 2024

Here's Why We're A Bit Worried About Abliva's (STO:ABLI) Cash Burn Situation

Chairman of the Board recently bought kr494k worth of stock

Abliva AB (Publ) Announces First Patient Dosed in the Falcon Study

Abliva AB (Publ) Announces Resignation of Edwin Moses as Director

Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333

No independent directors

Abliva AB (publ), Annual General Meeting, Apr 27, 2023

Abliva AB (publ) to Report First Half, 2023 Results on Aug 18, 2023

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Director recently bought kr35m worth of stock

Abliva AB (publ) to Report Fiscal Year 2022 Results on Feb 24, 2023

No independent directors

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Abliva AB (publ) to Report Fiscal Year 2021 Results on Apr 29, 2022

Full year 2021 earnings: EPS misses analyst expectations

US Food and Drug Administration Approves Abliva's Investigational New Drug (IND) Application for KL1333

Third quarter 2021 earnings released: kr0.086 loss per share (vs kr0.03 loss in 3Q 2020)

We're Keeping An Eye On Abliva's (STO:ABLI) Cash Burn Rate

Abliva Reports Positive Clinical Phase 1A/B Results for KL1333 Including Signs of Efficacy in PMD Patients

Is Abliva (STO:ABLI) In A Good Position To Invest In Growth?

Abliva Completes Phase Ia/Ib Study with KL1333

Full year 2020 earnings released: kr0.24 loss per share (vs kr0.45 loss in FY 2019)

Revenue and earnings miss expectations

New 90-day low: kr0.74

Chief Executive Officer Erik Kinnmann has left the company

Abliva Announces CEO Changes, with Effect from February 3rd

New 90-day low: kr0.77

How Much Is Abliva AB (publ) (STO:ABLI) Paying Its CEO?

Third quarter 2020 earnings released: kr0.03 loss per share

Abliva AB (publ) to Report Fiscal Year 2021 Results on Feb 22, 2022

New 90-day low: kr0.78

New 90-day low: kr0.91

Abliva AB Announces Resignation of Magnus Persson From Board of Directors

Earnings released

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera